News from PPD, Omnicare, and Bio Nebraska – People on the move
Raymond Hill has become PPD's new chief executive officer and has been elected to the board of directors.
Hill comes to the firm from market research and consultancy company IMS Health, where he served as president of the IMS Consulting Group.
"With more than 20 years of experience in the life sciences arena, Ray brings keen strategic acumen as a proven leader who has grown global client services businesses in the pharmaceutical industry," said Fred Eshelman, executive chairman of PPD.
Read more about what this means for PPD here.
Bio Nebraska Life Sciences Association has appointed new executive leadership team in Phil Kozera and Kendra Wilson.
New executive director Kozera joins the team after being named chief operating officer of SCORR– the marketing team for Bio Nebraska – in August last year.
Wilson, who will take the role of assistant executive director, was also hired by SCORR earlier this year as an account coordinator.
“This change in leadership presents an opportunity for Bio Nebraska to add depth to our staff and expand our geographic footprint within the state,” said Jim McClurg Bio Nebraska executive board chairman.
Omnicare has named Kathleen McGuan as its new senior VP and chief compliance officer.
McGuan takes the role after working as the company’s interim chief compliance officer.
Before Omnicare, she was senior counsel and strategic advisor to the Life Sciences Health Industry Group for Reed Smith LLP, where she also practiced in her early career.
Omnicare CEO John Figueroa said of her appointment: "During the past several months, Kathleen has been invaluable in reshaping our strategy around compliance while cultivating relationships with various healthcare agencies.”
Cresset has announced that Martin Slater will become the new director of consulting.
Slater joins the company – who recently inked a major drug discovery deal with Redx Pharma – in time for the launch of its professional services division.
Prior to Cresset, he was senior research fellow at BioFocus where he worked with their SoftFocus library brand developing chemogenomic tools.
Rob Scoffin, CEO of Cresset, said: “The rapidly increasing demand for our expertise, demonstrated by our recent major collaboration with Redx Pharma, has led us to establish a dedicated Professional Services division.
“Martin’s unrivalled experience of using our tools on customer projects made him the ideal candidate to help drive this division forward.”
Charles Jensen has become the director of drug metabolism and pharmacokinetics (DMPK) for AMRI.
Jensen’s expertise in the field spans 20 years, 15 of which were served at Eli Lilly and Co., where he was most recently senior study director for drug development services for In Vitro Technologies.
AMRI hope Jensen’s appointment will support their drug discovery team as it becomes more involved in fully integrated discovery biology and chemistry programs.
Bruce Sargent, senior VP of drug discovery said: “At AMRI, we consider early ADMET profiling and pharmacokinetic analysis to be crucial components of the drug discovery process, and we are excited to have Dr. Jensen join us with his substantial experience in these fields.”
